Alaunos Therapeutics, Inc.

TCRTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1107421

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$5.0K	$2.9M	$398.0K	$0.00	$146.0K
Research and Development Expense	$16.3M	$25.0M	$49.6M	$52.7M	$34.1M
Operating Expenses	$34.3M	$38.0M	$77.9M	$80.4M	$54.1M
Operating Income (Loss)	-$34.3M	-$35.1M	-$77.5M	-$80.4M	-$53.9M
Interest Expense	—	$3.2M	$1.2M	—	—
Nonoperating Income (Expense)	-$873.0K	-$2.6M	-$1.2M	—	—
Net Income (Loss) Attributable to Parent	-$35.1M	-$37.7M	-$78.8M	-$80.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$8.3M	$64.9M	$94.9M	$146.3M	$109.1M
Assets, Current	$8.3M	$53.8M	$78.8M	$130.6M	$105.5M
Cash and Cash Equivalents, at Carrying Value	$6.1M	$39.1M	$76.1M	$115.1M	$79.7M
Liabilities	$2.0M	$26.4M	$36.8M	$22.4M	$14.1M
Liabilities, Current	$2.0M	$24.2M	$16.0M	$18.4M	$12.5M
Long-term Debt, Excluding Current Maturities	$0.00	$0.00	$16.3M	$0.00	—
Accounts Payable, Current	$616.0K	$1.4M	$1.4M	$960.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$30.1M	-$29.2M	-$61.5M	-$57.0M	-$49.5M
Net Cash Provided by (Used in) Investing Activities	$1.3M	-$193.0K	-$3.3M	-$9.8M	-$459.0K
Net Cash Provided by (Used in) Financing Activities	-$18.1M	$6.4M	$25.8M	$102.1M	$40.3M
Payments to Acquire Property, Plant, and Equipment	$197.0K	$216.0K	$3.3M	$9.8M	$459.0K
Payments for Repurchase of Common Stock	—	$45.0K	$0.00	—	$1.6M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)